3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cisplatin
90
Fluorouracil
76
Radiotherapy
63
Paclitaxel
58
Docetaxel
49
Oxaliplatin
48
Irinotecan
42
Leucovorin
32
Capecitabine
31
Carboplatin
27
Radiation
21
Surgical Procedures, Operative
20
Esophagectomy
20
pembrolizumab
15
Neoadjuvant Therapy
15
Bevacizumab
15
Cetuximab
13
Drug Therapy
12
Epirubicin
11
Chemotherapy, Adjuvant
9
S 1 (combination)
8
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Trastuzumab
7
Nivolumab
7
Erlotinib Hydrochloride
7
Surveys and Questionnaires
6
Panitumumab
6
Immunohistochemistry
6
Chemoradiotherapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled